source
- Gilead agrees to pay $1.28 billion upfront to China's PepStar for oral IL-23 inflammation drug candidateGilead Sciences announced a deal with Chinese biotech PepStar Therapeutics to acquire an early-stage oral IL-23 inhibitor. The agreement includes an upfront payment of roughly $1.28 billion for Pe…
- Lycia Therapeutics raises $318 million in IPO to fund protein degrader programsLycia Therapeutics, a biotech focused on protein-degrading medicines, priced its initial public offering at about $318 million. The proceeds will be used to advance three LYTAC drug candidates, in…